MANE
Veradermics, Incorporated
118.90$
+1.8%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | |
| – | +134.1% | -46.0% | +20.0% | +605.8% | +439.9% | -33.1% | – | |
| – | -274.9% | – | – | -565.3% | – | -117.1% | – | |
| – | – | -100.0% | – | – | -100.0% | – | – | |
| – | – | – | – | -831.9% | -7.7% | +173.7% | – | |
| – | – | – | – | – | – | – | – | |
| – | -83.3% | -98.5% | +735.7% | +13,769.4% | +80.0% | +64.5% | – | |
| – | -144.2% | – | – | – | +810.5% | +2.9% | – | |
| – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.